The role of cetuximab in the management of head and neck cancers

Expert Opinion on Biological Therapy

Volumn 12, Issue 4, 2012, Pages 517-528

  Kabolizadeh, Peyman ^a   Kubicek, Gregory J ^a   Heron, Dwight E ^a   Ferris, Robert L ^a   Gibson, Michael K ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; Chemo radiation; Cisplatin; EGFR; Head and neck cancer; Radiation treatment

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ACNE; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LOADING DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OROPHARYNX CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84858629127     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.667397     Document Type: Article

References (48)

1. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4:156-71 (Pubitemid 46358853)
2. Bourhis J, Amand C, Pignon JP. Update of MACH-NC (Meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004;22(Suppl):5505
3. Adelstein DJ, Li Y, Adams G, et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8
4. Calais G, Alfonsi M, Bardet E, et al. Randomized study comparing radiation alone RT versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6 (Pubitemid 30019568)
5. Wilting SM, Smeets SJ, Snijders PJ, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics 2009;2:32
6. Licitra L, Bergamini C, Mirabile A, Granata R. Targeted therapy in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2011;19:132-7
7. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500 (Pubitemid 38610250)
8. Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelialto-mesenchymal transition and activation of nuclear factor-kappaB signalling as characteristic of a high risk squamous cell carcinoma. Cancer Res 2006;66:8210-18 (Pubitemid 44299189)
9. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 2003;5:140-6 (Pubitemid 38898776)
10. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46 (Pubitemid 38429984)
11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from phase III randomised trial and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-8
12. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 11:1116-27
13. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988; 57:443-78
14. Van de Vijver MJ, Kumar R, Mendelsohn J. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem 1991;266:7503-8 (Pubitemid 21906393)
15. Bou-Assaly W, Mukherji S. Cetuximab (Erbitux). Am J Neuroradiol 2010;31:626-7
16. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Nat Cancer Inst 1993;85:1327-33 (Pubitemid 23249725)
17. Klyota A, Shintani S, Mihara M, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27KIP1 and p15INK4B and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 2002;63:92-8 (Pubitemid 34977943)
18. Wu X, Rubin M, Fan Z, et al. Involvement of p27 KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996; 12:1397-403
19. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-905
20. Mendelsohn J, Kawamoto T, Sato G, Sato J. Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. US4943533; 1990
21. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14 (Pubitemid 30106623)
22. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005;5:1085-93 (Pubitemid 41170037)
23. Cetuximab [Erbitux ] package insert 2006. Available from: http://patient. cancerconsultants.com/druginserts/ Cetuximab.pdf [Last accessed 21 February 2012]
24. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13 (Pubitemid 32708671)
25. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43 (Pubitemid 32591441)
26. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78 (Pubitemid 43209104)
27. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or incombination with cetuximab. J Clin Oncol 2007;25:2191-7 (Pubitemid 46954642)
28. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27
29. Burtness B, Goldwasser M A, Flood W, et al. Phase III randomized trial of cisplatin placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-54 (Pubitemid 46211507)
30. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-87
31. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77
32. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7 (Pubitemid 46954639)
33. Mesia R, Rueda A, Vera R, et al. Safety report of a randomized phase II trial to evaluate the combination of cetuximab plus accelerated concomitant boost radiotherapy (RT) followed or not by cetuximab monotherapy in patients (pts) with locally-advanced squamous cell carcinoma of the oropharynx. J Clin Oncol 2008; 26(Suppl):6076
34. Mesia R, Rueda A, Vera R, et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally-advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial. J Clin Oncol 2010; 28(Suppl):5534
35. Argiris A, Heron D, Smith R, et al. Induction docetaxel, cisplatin and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally-advanced head and neck cancer. J Clin Oncol 2010;28:5294-300
36. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized Phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with and without cetuximab for stage III/IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011;20(Suppl):5500
37. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73 (Pubitemid 44453332)
38. Na II, Kang HJ, Cho SY, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007;43:520-6 (Pubitemid 46177596)
39. Pryor DI, Solomon B, Porceddu SV. The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia Pac J Clin Oncol 2011;7:236-51
40. Young R, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16INK4A and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011;20:1230-7
41. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009;74:553-61
42. Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011; 16:228-38
43. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1864-71
44. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter Phase II study of erlotinib an oral epidermal growth factor receptor tyrosine kinase ihibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85 (Pubitemid 41095117)
45. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/ M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006;24(Suppl):5568
46. Seiwert TY, Clement PM, Cupissol D, et al. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study. J Clin Oncol 2010;28(Suppl):5501
47. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-73 (Pubitemid 47372619)
48. Sabichi AL, Kies MS, Glisson BS, et al. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 2010;28(Suppl):5532